Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), or urgent HF visits in adults with symptomatic chronic HF, UK Pharma major AstraZeneca (LSE: AZN) announced this morning.
The company noted that Forxiga has previously been approved in China for HF patients with reduced ejection fraction (HFrEF) meaning that the drug is now approved in China to reduce the risk of cardiovascular death and hospitalizations in adult patients with symptomatic chronic HF regardless of ejection fraction phenotype.
The drug generated global sales of $4.4 billion for AstraZeneca last year. It is expected to see an increase in uptake with the approval of additional indications, granting AstraZeneca a majority share of the total HF market, according to GlobalData analysts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze